Companies / Israel
Innovative Pharmaceuticals Help Drive Teva Growth
May 2007 | Industry NewsIsraeli firm Teva 's second innovative drug offering Azilect (rasagiline tablets), which treats Parkinson's disease, has continued its successful market entry helping the company to record another quarter of strong results. In Q107, Teva's sales hit US$2.1bn, an increase of 24% q-o-q and BMI expects the good performance to continue as the company benefits from its multi-billion dollar acquisition of IVAX.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Middle East & Africa Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Middle East & Africa Pharma & Healthcare Insight please click on the trial link below.
